The role of intensive blood pressure control in diabetes mellitus
https://doi.org/10.62751/2713-0177-2025-6-2-07
Abstract
Arterial hypertension (AH) is one of the most common comorbidities in patients with diabetes mellitus (DM), significantly increasing the risk of adverse outcomes and cardiovascular complications. The coexistence of these conditions is driven by shared pathophysiological mechanisms of metabolic disorders, as well as hereditary and acquired factors. Frequent coexistence of AH and DM requires certain principles of patient management and control. Blood pressure (BP) control, along with control of glycemia and lipid profile parameters, is one of the most important components of complex therapy of DM and its complications. The question of at what BP values it is necessary to initiate therapy and what should be the target BP values in patients with diabetes has been controversial for many years. Another issue requiring attention is the management of “prehypertension” or high normal BP in patients with DM. In this article, we will review the main benefits and risks of intensive BP control in patients with diabetes, as well as strategies for managing patients with prehypertension according to current clinical guidelines and the latest research data.
About the Authors
S. V. Panteleeva
Pirogov Russian National Research Medical University
Russian Federation
Russian Federation
Sofia V. Panteleeva – 2nd year clinical resident of the Department of endocrinology, Institute of Clinical Medicine
Moscow
M. Ya. Izmailova
Pirogov Russian National Research Medical University
Russian Federation
Russian Federation
Maryam Ya. Izmailova – assistant at the Department of endocrinology
Moscow
References
1. Wang Z, Yang T, Fu H. Prevalence of diabetes and hypertension and their interaction effects on cardio-cerebrovascular diseases: A cross-sectional study. BMC Public Health. 2021; 21(1): 1224. doi: 10.1186/s12889-021-11122-y.
2. Кобалава Ж.Д., Конради А.О., Недогода С.В. с соавт. Артериальная гипертензия у взрослых. Клинические рекомендации 2024. Российский кардиологический журнал. 2024; 29(9): 6117. doi: 10.15829/1560-4071-2024-6117.
3. Kreutz R, Brunstrom M, Burnier M et al. 2024 European Society of Hypertension clinical practice guidelines for the management of arterial hypertension. Eur J Intern Med. 2024; 126: 1–15. doi: 10.1016/j.ejim.2024.05.033.
4. Whelton PK, Carey RM, Aronow WS et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APHA/ASH/ASPC/ NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: executive summary: A report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines. J Am Coll Cardiol. 2018; 71(19): 2199–269. doi: 10.1016/j.jacc.2017.11.005.
5. Muntner P, Carey RM, Gidding S et al. Potential US population impact of the 2017 ACC/AHA high blood pressure guideline. Circulation. 2018; 137(2): 109–18. doi:10.1161/CIRCULATIONAHA.117.032582.
6. SPRINT Research Group; Wright JT Jr, Williamson JD, Whelton PK et al. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med. 2015; 373(22): 2103–16. doi: 10.1056/NEJMoa1511939.
7. Jia G, Sowers JR. Hypertension in diabetes: An update of basic mechanisms and clinical disease. Hypertension. 2021; 78(5): 1197–205. doi: 10.1161/HYPERTENSIONAHA.121.17981.
8. Sowers JR. Diabetes mellitus and vascular disease. Hypertension. 2013; 61(5): 943–47. doi: 10.1161/HYPERTENSIONAHA.111.00612.
9. Hill MA, Yang Y, Zhang L et al. Insulin resistance, cardiovascular stiffening and cardiovascular disease. Metabolism. 2021; 119: 154766. doi: 10.1016/j.metabol.2021.154766.
10. Whaley-Connell A, Sowers JR. Aldosterone and risk for insulin resistance. Hypertension. 2011; 58(6): 998–1000. doi: 10.1161/HYPERTENSIONAHA.111.182782.
11. Zhou B, Carrillo-Larco RM, Danaei G et al. Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: A pooled analysis of 1201 population-representative studies with 104 million participants. Lancet. 2021; 398(10304): 957–80. doi: 10.1016/S0140-6736(21)01330-1.
12. Бойцов С.А., Драпкина О.М., Шляхто Е.В. с соавт. Исследование ЭССЕ-РФ (Эпидемиология Сердечно-Сосудистых заболеваний и их факторов риска в регионах Российской Федерации). Десять лет спустя. Кардиоваскулярная терапия и профилактика. 2021; 20(5): 3007. doi: 10.15829/1728-8800-2021-3007.
13. Hansson L, Zanchetti A, Carruthers SG et al. Effects of intensive blood-pressure lowering and low dose aspirin in patient with hypertension: Principal results of the HOT randomized trial. Lancet 1998; 351(9118): 1755–62. doi: 10.1016/s0140-6736(98)04311-6.
14. Rationale and design of the ADVANCE study: A randomised trial of blood pressure lowering and intensive glucose control in high-risk individuals with type 2 diabetes mellitus. Action in diabetes and vascular disease: PreterAx and DiamicroN modified-release controlled evaluation. J Hypertens Suppl. 2001; 19(4): S21–28.
15. Schrier RW, Estacio RO, Esler A, Mehler P. Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes. Kidney Int. 2002; 61(3): 1086–97. doi: 10.1046/j.1523-1755.2002.00213.x.
16. American Diabetes Association Professional Practice Committee. Introduction and methodology: Standards of Care in Diabetes-2024. Diabetes Care. 2024; 47(Supplement_1): S1–S4. doi: 10.2337/dc24-SINT.
17. Bi Y, Li M, Liu Y et al.; BPROAD Research Group. Intensive blood-pressure control in patients with type 2 diabetes. N Engl J Med. 2025; 392(12): 1155–67. doi: 10.1056/NEJMoa2412006.
18. Vasan R, Larson M, Leip E et al. Assessment of frequency of progression to hypertension in nonhypertensive participants in the Framingham Heart Study: A cohort study. Lancet. 2001; 358 (9594): 1682–86. doi: 10.1016/S0140-6736(01)06710-1.
19. Cuspidi C, Facchetti R, Bombelli M et al. High normal blood pressure and left ventricular hypertrophy echocardiographic findings from the PAMELA population. Hypertension. 2019; 73(3): 612–19. doi: 10.1161/HYPERTENSIONAHA.118.12114.
20. Nakai H, Takeuchi M, Nishikage T et al. Subclinical left ventricular dysfunction in asymptomatic diabetic patients assessed by two-dimensional speckle tracking echocardiography: Correlation with diabetic duration. Eur J Echocardiogr. 2009; 10(8): 926–32. doi: 10.1093/ejechocard/jep097.
Review
For citations:
Panteleeva S.V., Izmailova M.Ya. The role of intensive blood pressure control in diabetes mellitus. FOCUS. Endocrinology. 2025;6(2):58–63. (In Russ.) https://doi.org/10.62751/2713-0177-2025-6-2-07
Views:
36
Email this article 